11.06.2013 • Topics

Gelest expands its Specialty Silane, Silicone and Metal-Organic Materials business

Gelest continues to strengthen its position as a manufacturer and supplier of commercial and research scale organosilicon compounds, metal-organic compounds and silicones to the global marketplace. It has extended its reach into Europe through the acquisition of a warehouse and logistics center located in Industriepark Griesheim, Frankfurt/Main Germany.

The expansion is in response to the increased demand for silanes and metal-organics in the pharmaceutical and diagnostic markets. Gelest also sees significant opportunities for silicone products in the specialty coatings and instrumentation markets.  For the first time, the company will begin offering research quantities of its specialty materials directly throughout Europe. 

Just a few minutes from Frankfurt International Airport and centrally located within the European market, Gelest is poised to support research and bulk materials quickly and cost effectively for all European customers within a similar time-zone.

The fully equipped warehouse and logistics center is staffed with qualified personnel and meets all European legal requirements. Its capabilities include:
• Catalog and bulk sales
• Import and export handling/customs clearance
• Dangerous goods management for road, air and sea transport
• REACH registration
• Sample handling and shipments
• Service center and E-commerce order processing

 

Company

LivChem Logistics GmbH

Stroofstrasse 27 Geb. 2901
65933 Frankfurt am Main
Germany

Company contact







Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read